Cortex receives additional Ampakine patents and notices of allowance.
This patent claims the use of any/all AMPA-receptor modulating compounds for treating a loss of libido, a condition that commonly occurs with aging.
Loss of libido also occurs as a result of other neurological and psychiatric conditions and is a side effect of certain classes of medication. "Given the brisk sales of medications that treat sexual dysfunction of vascular origins and the lack of drugs on the horizon that might address loss of libido, we view this as an important potential application for the AMPAKINE pharmacology," stated Gary Rogers, PhD, Cortex senior vice president of pharmaceutical research.
In addition, the Australian patent office has issued a patent entitled, "Treatment of Clinical Depression by Glutamatergic Upmodulators." "This patent contains broad claims for all drugs that enhance the effect of AMPA receptors for use in treating depression," stated Vincent F. Simmon, PhD, Cortex president and chief executive officer. The same patent application has also been filed in the United States and Europe by Cortex, which has licensed this and the above patent from the University of California (Irvine, CA).
The USPTO also issued patent number 6,110,935, entitled, "Benzofurazan Compounds for Enhancing Glutamatergic Synaptic Responses." "This patent , which previously issued in Great Britain, claims second generation compounds that represent substantial improvements in activity over CX516," added Dr. Rogers.
In New Zealand, the patent office has given Cortex a notice of allowance for a patent entitled, "Benzofurazan Compounds which Enhance AMPA Receptor Activity." Cortex has also received a notice of allowance from the Canadian patent office for its patent entitled, "Benzoyl Piperidines/Pyrrolidines for Enhancing Synaptic Response," a patent that has already issued in the United States.
"I am gratified to see the issuance of our broad use patents in the US, and in other countries as well," Dr. Simmon continued. "This brings our total portfolio on the AMPAKINEs to 17 issued and allowed patents, with 58 additional patent applications in various stages of review throughout the world. Cortex has a combination of broad patents, which cover the use of AMPA-receptor modulating compounds to treat a variety of neurological and psychiatric conditions, and patents for chemical structures, which modulate the effect of glutamate on AMPA receptors. We believe this intellectual property base places Cortex in a very strong and competitive position."
Cortex is a neuroscience company focused on novel drug therapies for neurological and psychiatric disorders. The company is pioneering a class of proprietary pharmaceuticals called AMPAKINEs, which act to increase the strength of signals at connections between brain cells. The weakening or loss of these connections is thought to be responsible for memory difficulties from Alzheimer's disease and to contribute to cognitive dysfunction in schizophrenia. A recently completed study with AMPAKINEs in patients with schizophrenia indicated improvement in a number of symptoms also common to patients with ADHD. Cortex has alliances with Servier for the potential treatment of declines in cognitive performance associated with aging and neurodegenerative diseases, including Alzheimer's disease; NV Organon for the potential treatment of schizophrenia, and possibly depression; and with Shire Pharmaceuticals Group for the evaluation and potential licensing of AMPAKINEs as a treatment for attention deficit hyperactivity d! isorder (ADHD).
Health industry estimates indicate that more than four million Americans are victims of Alzheimer's disease, with that number expected to double over the next 20 years as the United States population ages. The worldwide incidence of schizophrenia is approximately one percent of the population. It accounts for 2.5% of all United States health care costs and 75% of expenditures for mental health care. It is estimated that approximately 6% of school age children in the United States have Attention Deficit/Hyperactivity Disorder. While there are approved medications for each of these neurological conditions, there is an unmet medical need for new drugs with improved efficacy and/or reduced side effects.
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||in United States, Australia and New Zealand, for antidepressants|
|Comment:||Cortex receives additional Ampakine patents and notices of allowance.(in United States, Australia and New Zealand, for antidepressants)|
|Publication:||BIOTECH Patent News|
|Article Type:||Brief Article|
|Date:||Nov 1, 2000|
|Previous Article:||Keygene and PIC align to accelerate genetic improvement.|
|Next Article:||Valentis announces improved Geneswitch gene regulation system.|